AEON Biopharma, Inc. (NASDAQ:AEON – Get Free Report) insider Alexander Blair Wilson purchased 135,706 shares of the company’s stock in a transaction on Friday, November 20th. The stock was purchased at an average price of $0.13 per share, with a total value of $17,641.78. Following the completion of the transaction, the insider owned 2,318,711 shares of the company’s stock, valued at approximately $301,432.43. This trade represents a 6.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
AEON Biopharma Stock Performance
Shares of NASDAQ AEON traded down $0.01 during midday trading on Friday, reaching $0.12. The stock had a trading volume of 1,155,110 shares, compared to its average volume of 2,679,296. The company has a market capitalization of $8.80 million, a price-to-earnings ratio of 0.68 and a beta of 0.68. AEON Biopharma, Inc. has a 12-month low of $0.11 and a 12-month high of $1.45. The stock has a 50-day moving average of $0.24 and a 200-day moving average of $0.61.
Institutional Investors Weigh In On AEON Biopharma
An institutional investor recently bought a new stake in AEON Biopharma stock. Nantahala Capital Management LLC acquired a new stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,400,000 shares of the company’s stock, valued at approximately $1,298,000. Nantahala Capital Management LLC owned 8.82% of AEON Biopharma at the end of the most recent reporting period. Institutional investors own 22.78% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on AEON shares. Laidlaw assumed coverage on AEON Biopharma in a report on Wednesday, September 9th. They issued a “buy” rating and a $1.80 price target on the stock. Lake Street Capital restated a “buy” rating and set a $2.00 price objective (up from $1.00) on shares of AEON Biopharma in a research report on Thursday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $1.20 target price (down from $5.00) on shares of AEON Biopharma in a report on Friday, August 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1.67.
View Our Latest Analysis on AEON Biopharma
AEON Biopharma Company Profile
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions using botulinum toxin. Its lead candidate, ABP-450, is an investigational botulinum toxin type A product being studied for therapeutic uses. The company’s development programs include chronic migraine and cervical dystonia. ABP-450 is not an approved treatment for these conditions, and its safety and effectiveness have not been established for these uses. AEON has described its rights to develop and commercialize ABP-450 for therapeutic indications in the United States and Canada.
Featured Articles
- Five stocks we like better than AEON Biopharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
